Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464006 | 0.81 | SORD (0.51) | SORDCYP1A2CYP2C9CYP2C19PIK3CA | |
| SCHEMBL459151 | 0.81 | SORD (0.51) | SORDCYP1A2CYP2C9CYP2C19PIK3CA | |
| SCHEMBL9767811 | 0.79 | — | — | |
| SCHEMBL15416119 | 0.78 | HRH3 (0.43) | SORDHRH3TLR9TLR8TLR7 | |
| SCHEMBL18751497 | 0.77 | USP2 (0.45) | SORDHRH3TLR9TLR8TLR7 | |
| SCHEMBL30775404 | 0.71 | SORD (0.56) | SORDGPR119RIPK1 | |
| SCHEMBL4453478 | 0.71 | SORD (0.56) | SORDGPR119RIPK1 | |
| SCHEMBL30309936 | 0.71 | MAPT (0.49) | HRH3CYP11B2HSD11B1CYP1A2CYP3A4 | |
| SCHEMBL15779145 | 0.71 | MAPT (0.49) | HRH3CYP11B2HSD11B1CYP1A2CYP3A4 | |
| SCHEMBL27903580 | 0.71 | GPR119 (0.42) | SORDGPR119CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975906-B2 | Tricyclic heterocycle derivatives having HIV replication inhibitory effect | SHIONOGI & CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170107234-A1 | TRICYCLIC HETEROCYCLE DERIVATIVES HAVING HIV REPLICATION INHIBITORY EFFECT | SHIONOGI & CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107234-A1 | TRICYCLIC HETEROCYCLE DERIVATIVES HAVING HIV REPLICATION INHIBITORY EFFECT | NR4A1, NR4A3, NR0B1 | SORD 2795/4885HRH3 790/4885MAPK11 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.